Suven Pharma Shares Jump 4.26% After Q3FY25 Net Profit Surges to ₹82.9 Crore

Suven Pharmaceuticals Ltd announced a significant 77.1% year-on-year (YoY) increase in net profit for the third quarter of FY25, reporting ₹82.9 crore compared to ₹46.8 crore in the same period last year. Revenue from operations also saw a strong rise, jumping 39.8% YoY to ₹307.2 crore from ₹219.8 crore in Q3FY24.

EBITDA and Margins See Strong Growth

At the operating level, Suven Pharma’s EBITDA (earnings before interest, tax, depreciation, and amortisation) soared by 78.2% YoY to ₹117.8 crore from ₹66 crore. The EBITDA margin improved significantly, expanding to 38.4% from 30.1% in the year-ago period. The company’s gross margins for the quarter stood at 71.5%, while adjusted EBITDA margins came in at 38.7%.

Pharma CDMO Segment Fuels Growth

The primary driver of Suven Pharma’s Q3FY25 performance was the pharma contract development and manufacturing organisation (CDMO) segment, which recorded a remarkable 101% YoY growth. This surge was supported by the company’s continued research and development (R&D) investments and business development initiatives.

In the pharma CDMO segment, the company also witnessed a twofold YoY increase in requests for quotations (RFQs) for the first nine months of FY25, reflecting sustained demand across different stages, driven by favourable macroeconomic trends.

Expansion in Drug Development Pipeline

During the quarter, Suven Pharma added two new molecules to its pipeline—one progressing to phase 3 and another being directly included in phase 3 as a lateral addition. This brings the total number of active phase 3 projects to 15, covering nine different molecules.

Capital Expenditure and Financial Position

For the first nine months of FY25, Suven Pharma incurred a capital expenditure of ₹938 million. The company also generated ₹1.33 billion in free cash flow, further strengthening its financial position. As of the end of Q3FY25, it maintained a cash and bank balance of ₹2.82 billion.

Stocks Performance

On February 13, 2025, Suven Pharmaceuticals share price traded 4.26% higher at ₹1,090.23 at 9:18 AM (IST). Suven Pharmaceuticals’s share price reached a 52-week high of ₹1,359 on December 2, 2024, and a 52-week low of ₹597 on June 04, 2024. As per BSE, the total traded volume for the stock stood at 349 shares with a turnover of ₹3.79 lakhs.

At the current price, Suven Pharmaceuticals shares are trading at a price-to-earnings (P/E) ratio of 119.46x, based on its trailing 12-month earnings per share (EPS) of ₹9.71, and a price-to-book (P/B) ratio of 13.39, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.